Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds

Autor(es)

dos Santos Fernandes, Guilherme Felipe ; Chin, Chung Man ; Dos Santos, Jean Leandro

• Tipo de documento: Artigo de Revisão
• Fonte: PHARMACEUTICALS; v. 10, n. 2 JUN 2017.
• Citações Web of Science: 10

Resumo

Tuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest number of deaths worldwide. The increased number of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years. The scenario of drug discovery becomes alarming when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compounds with potent antituberculosis activity against MDR-TB strains. Herein, active compounds against MDR-TB with minimum inhibitory concentrations (MICs) less than 11 mu M and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed. (AU)

• Processo FAPESP: 16/09502-7 - Planejamento, síntese e atividade antituberculose de novas oxazolidinonas úteis ao tratamento da tuberculose multirresistente
• Beneficiário: Guilherme Felipe dos Santos Fernandes
• Modalidade de apoio: Bolsas no Brasil - Doutorado